Aviragen Therapeutics (AVIR) Reports Q4 Loss of $0.15/Share

Aviragen Therapeutics (NASDAQ: AVIR) reported Q4 EPS of ($0.15), versus ($0.18) reported last year.

For earnings history and earnings-related data on Aviragen Therapeutics (AVIR) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Atea Pharmaceuticals (AVIR) PT Raised to $7 at Morgan Stanley
• Outlook Therapeutics (OTLK) Misses Q3 EPS by 9c